Tuesday morning the Tampa Bay Business Journal highlighted “a Tampa biotech” for its advancements in the development of potential drug therapies for “difficult-to-treat”. That company? Oxis Biotech.
Following the company’s most recent announcements, the press has begun to pick up on the company’s progress. “The drug candidates from Oxis Biotech are targeted at the treatment of triple-negative breast cancer and multiple myeloma. Triple-negative breast cancer, which does not respond to many therapies currently available, affects about 23,000 to 46,000 newly diagnosed patients every year, including younger people, African Americans or Hispanics and those with a certain type of gene mutation. Multiple myeloma, which causes cancer cells to accumulate in the bone marrow, affects about 26,850 people annually in the United States.”
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
